

## PERSONAL INFORMATION **Andrea Doria**



📍 Rheumatology Unit  
Department of Medicine  
University of Padova  
Via 8 Febbraio, 2 – 35122 Padova



State personal website(s)

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor (RTDA-RTDB)	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

### Work Experience

From 1988 to 1990  
Hospital of Belluno, Adria e Rovigo  
Outpatient clinic of Rheumatology  
Consultant  
Taking care of outpatients affected with Rheumatic diseases

FROM 1990 TO 2006  
University-Hospital of Padova  
Rheumatology  
Assistant Professor of Rheumatology, Padova University School of Medicine  
Taking care of inpatients and outpatients affected with rheumatic disease; Lecturer at the Postgraduate School of Rheumatology

From 2006 up to 30/09/2025  
University-Hospital of Padova  
Rheumatology  
Full Professor of Rheumatology, Padova University School of Medicine  
Head of the Rheumatology Unit, Department of Internal Medicine, School of Medicine, University of Padova.  
Director of Postgraduate School on Rheumatology of University of Padua

From 1/10/2025 up to now  
Consultant Rheumatology  
Rheumatology Unit, Department of Internal Medicine, School of Medicine, University of Padova

### Education and training

From 1976 to 1982  
Padova University School of Medicine  
Medical training  
Medical degree

From 1982 to 1986  
University of Padova, Postgraduate School of Rheumatology  
Residency in Rheumatology  
Training in Rheumatology

Specialist in Rheumatology

### Work Activities **European grants**

"A phase 2b Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients with Knee Osteoarthritis (ADIPOA 2)" Research started on 20th September 2016 under the funding of the European Union (Grant agreement n° 643809). The European Union funding ended on 31st December 2019.

"TAXONOMY, TREATMENT, TARGETS AND REMISSION: 3TR. SLE STUDY" This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Awards, Editorial, Activity, Invited presentations, grants LAST 5 years, Patents

**Additional Information**

In 2022 the Rheumatology Unit, directed by Prof Doria, was appointed EULAR Center of Excellence 2022-2027

Prof Doria participates on the editorial boards of several Rheumatology and Immunology journals: *Lupus*, *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews*, *Journal of Autoimmunity*, *Experimental Biology and Medicine*,

Professor Doria has organised over ten international conferences on autoimmunity and was involved as "expert" in the European League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations. Professor Doria is a member of the Lupus Academy Steering Committee and co-Chaired the 4th Annual Meeting held in Rome 27th February-1st March 2015 and the 9th Annual Meeting held on-line 11-13th September 2020. He was the Chair of the 10th European Lupus Meeting, held in Venice (Italy) 5-8th October 2016 and the Chair of the 14th International Congress on Systemic Lupus Erythematosus held in virtual format from 6th to 9th October 2021

In November 2022 he was appointed incoming President of the Italian Society of Rheumatology (SIR) and in November 2024 President of the Italian Society of Rheumatology (2024-2026). He was Council member of the Italian College of Rheumatology (CRO) between 1999 and 2005 and a Council member of the Italian Society of Rheumatology (SIR) from 2007 to 2010, from 2013 to 2015, and from 2018 to 2020. In 2016 he founded the European Lupus Society (SLEuro) and was the first President of the Executive Committee. He currently serves as Treasurer of the Society. He is a member of the Lupus Academy Steering Committee, the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group, and the OMERACT SLE Working Group.

Number of total publications in peer-review journals in the last ten years : **267**  
/total number of citations: **30,016**; H index **99**

Replace with max 12 relevant publications of last 12 years with doi

1. Giollo A, Salvato M, Frizzera F, Khalid K, Luozzo LD, Capita M, Garaffoni C, Lanza G, Fedrigo M, Angelini A, Silvagni E, Doria A. Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis. **Ann Rheum Dis.** 2026 Jan;85(1):91-102. doi: 10.1016/j.ard.2025.07.023. Epub 2025 Aug 22. PMID: 40846588
2. Gatto M, Frontini G, Furlan C, Calatroni M, Cruciani C, Reggiani F, Bellis E, Iaccarino L, Sinico RA, Moroni G, Doria A. Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis. **Ann Rheum Dis.** 2025 Apr;84(4):594-600. doi: 10.1016/j.ard.2025.02.004. Epub 2025 Feb 28. PMID: 40023731.
3. Zen M, Gatto M, Doria A. Defining the targets in SLE management: insights and unmet gaps. **Ann Rheum Dis.** 2022 Aug 25;ard-2022-222991. doi: 10.1136/ard-2022-222991.
4. Moroni G, Gatto M, Tamborini F, Quagliani S, Radice F, Saccon F, Frontini G, Alberici F, Sacchi L, Binda V, Trezzi B, Vaglio A, Messa P, Sinico RA, Doria A. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. **Ann Rheum Dis.** 2025 Apr;84(4):594-600. doi: 10.1136/annrheumdis-2020-216965. Epub 2020 Jun 5. PMID: 32503858.
5. Saccon F, Zen M, Gatto M, Margiotta DPE, Afeltra A, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Frontini G, Moroni G, Dall'Ara F, Tincani A, Signorini V, Mosca M, Frigo AC, Iaccarino L, Doria A. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. **Ann Rheum Dis.** 2020 Jul;79(7):943-950. doi: 10.1136/annrheumdis-2020-217070. Epub 2020 Apr 22. PMID: 32321721.
6. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. **Nat Rev Rheumatol.** 2019 Jan;15(1):30-48. doi: 10.1038/s41584-018-0133-2. PMID: 30538302.
7. Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, Punzi L, Doria A. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. **Ann Rheum Dis.** 2018 Jan;77(1):104-110. doi: 10.1136/annrheumdis-2017-211613. Epub 2017 Sep 26. PMID: 28970217.
8. Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. **Arthritis Rheumatol.** 2018 Aug;70(8):1256-1264. doi: 10.1002/art.40511. Epub 2018 Jun 15. PMID: 29671280; PMCID: PMC6099508.
9. Moroni G, Vercelloni PG, Quagliani S, Gatto M, Gianfreda D, Sacchi L, Raffiotta F, Zen M, Costantini G, Urban ML, Pieruzzi F, Messa P, Vaglio A, Sinico RA, Doria A. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. **Ann Rheum Dis.** 2018 Sep;77(9):1318-1325. doi: 10.1136/annrheumdis-2017-212732. Epub 2018 May 5. PMID: 29730634.
10. Zen M, Iaccarino L, Gatto M, Bettio S, Saccon F, Ghirardello A, Punzi L, Doria A. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. **Ann Rheum Dis.** 2017 Mar;76(3):562-565. doi: 10.1136/annrheumdis-2016-210154. Epub 2016 Nov 24. PMID: 27884821.
11. Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, Punzi L, Doria A. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. **Ann Rheum Dis.** 2015 Dec;74(12):2117-22. doi: 10.1136/annrheumdis-2015-207347. Epub 2015 Jul 29. PMID: 26223434.
12. Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, Guillemin F, Kobelt G, Maurel F, Garofano A, Perna A, Murray M, Schmitt C, Boucot I. Annual direct medical cost of active systemic lupus erythematosus in five European countries. **Ann Rheum Dis.** 2014 Jan;73(1):154-60. doi: 10.1136/annrheumdis-2012-202443. Epub 2012 Dec 21. PMID: 23264339.

21/01/2026

Certifico che quanto riportato sopra corrisponde al vero



**DIPARTIMENTO DI MEDICINA DEI SISTEMI  
U.O.C. DI REUMATOLOGIA**

January 31, 2026

Application for Re-election to the SLEuro Executive Committee (2027–2028)

Dear Members of the SLEuro Assembly and Nominating Committee,  
I am writing to submit my application for re-election to the SLEuro Executive Committee for the 2027–2028 term, and to confirm my willingness to continue serving the Society as Treasurer.

As a founder of SLEuro in 2016 and its first President, I have been closely involved in the Society's development from its earliest stages. Together with the founding members, my primary goal was to establish a strong and credible European scientific society dedicated to systemic lupus erythematosus, capable of fostering collaboration, advancing research, and promoting high-quality education across Europe.

Over the years, I have remained actively engaged in the growth of SLEuro, contributing to its scientific and organizational consolidation. I have consistently supported the development of SLEuro's scientific activities, meetings, and educational initiatives, as well as its positioning within the broader European rheumatology and immunology landscape. It has been extremely gratifying to see SLEuro evolve into a well-recognized and respected platform for clinicians, researchers, and young investigators with a shared interest in SLE.

While my formal role within the Executive Committee has been that of Treasurer, my contribution has extended beyond financial oversight, focusing on continuity, institutional memory, and strategic support to the Executive Committee. I believe that this long-standing involvement and deep knowledge of the Society's history and mission can continue to be valuable as SLEuro moves forward into its next phase of development.

I am highly motivated to continue serving SLEuro and to support the Executive Committee in strengthening the Society's scientific impact, visibility, and collaborative network across Europe. I remain fully committed to SLEuro's mission and to contributing constructively to its future growth.

Thank you for considering my application. I would be honored to continue working with the Executive Committee and the SLEuro membership for the continued success of our Society.  
Yours sincerely,



Prof. Andrea Doria  
Professor of Rheumatology  
Rheumatology Unit, University of Padua, Italy  
***EULAR Center of Excellence in Rheumatology 2022-2027***  
President of Italian Society of Rheumatology